The latest study will test setidegrasib versus docetaxel in second-line lung cancer.
ApexOnco Front Page
Recent articles
What could be the four HengRui assets picked up by Bristol?
But the overall survival benefit in prostate cancer is still driven by HRR mutations.
Phase 1 data give investors a benchmark for mevrometostat's pivotal Mevpro-1 trial.
AbbVie follows Gilead in throwing Xilio a lifeline.
The deal isn’t done, but would be Merck’s biggest oncology buy.
Padcev still looks good in first-line bladder, but Pfizer hopes to make a mark in muscle-invasive disease.
Orca-T is said to hit in a pivotal trial, but the comparator regimen could be debated.